Clinical Evaluation of SRT-017 in Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer

This is a single-arm, open-label study to evaluate the safety, tolerability and preliminary anti-tumor efficacy of SRT-017 radioligand therapy in patients with PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC). All eligible participants will receive SRT-017 intravenous treatment. The primary objectives are to assess safety and tolerability. Secondary objectives include radiation dosimetry, pharmacokinetics, and preliminary antitumor activity.

Trial Details

NCT ID
NCT07798778
Phase
EARLY_PHASE1
Sponsor
Affiliated Hospital of Jiangnan University
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • SRT-017
Locations (sample)
  • Wuxi, Jiangsu, China|31.56887,120.28857

Key Eligibility Criteria

  • Male participants aged 18 years or older.
  • Histologically or cytologically confirmed prostate adenocarcinoma with metastatic castration-resistant prostate cancer (mCRPC). mCRPC is defined as…
  • Disease progression after treatment with at least one novel androgen-axis drug (NAAD), including abiraterone, enzalutamide, apalutamide, or darolut…
  • Prior chemotherapy, or participants who are ineligible for chemotherapy or decline chemotherapy.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →